Skip to main content
Top
Published in: Critical Care 5/2006

Open Access 01-10-2006 | Research

Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome

Authors: Saad Nseir, Christophe Di Pompeo, Hélène Brisson, Florent Dewavrin, Stéphanie Tissier, Maimouna Diarra, Marie Boulo, Alain Durocher

Published in: Critical Care | Issue 5/2006

Login to get access

Abstract

Introduction

The aim of this study was to determine incidence, risk factors, and impact on outcome of intensive care unit (ICU)-acquired Stenotrophomonas maltophilia.

Methods

This prospective observational case-control study, which was a part of a cohort study, was conducted in a 30-bed ICU during a three year period. All immunocompetent patients hospitalised >48 hours were eligible. Patients with non-fermenting Gram-negative bacilli (NF-GNB) at ICU admission were excluded. Patients without ICU-acquired S. maltophilia who developed an ICU-acquired NF-GNB other than S. maltophilia were also excluded. Screening (tracheal aspirate and skin, anal, and nasal swabs) for NF-GNB was performed in all patients at ICU admission and weekly. Univariate and multivariate analyses were performed to determine risk factors for ICU-acquired S. maltophilia and for ICU mortality.

Results

Thirty-eight (2%) patients developed an S. maltophilia ICU-acquired colonisation and/or infection and were all successfully matched with 76 controls. Chronic obstructive pulmonary disease (COPD) and duration of antibiotic treatment (odds ratio [OR] [95% confidence interval (CI)] = 9.4 [3 to 29], p < 0.001, and 1.4 [1 to 2.3], p = 0.001, respectively) were independently associated with ICU-acquired S. maltophilia. Mortality rate (60% versus 40%, OR [95% CI] = 1.3 [1 to 1.7, p = 0.037]), duration of mechanical ventilation (23 ± 16 versus 7 ± 11 days, p < 0.001), and duration of ICU stay (29 ± 21 versus 15 ± 17 days, p < 0.001) were significantly higher in cases than in controls. In addition, ICU-acquired infection related to S. maltophilia was independently associated with ICU mortality (OR [95% CI] = 2.8 [1 to 7.7], p = 0.044).

Conclusion

COPD and duration of antibiotic treatment are independent risk factors for ICU-acquired S. maltophilia. ICU-acquired S. maltophilia is associated with increased morbidity and mortality rates. ICU-acquired infection related to S. maltophilia is an independent risk factor for ICU mortality.
Appendix
Available only for authorised users
Literature
1.
go back to reference Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D: Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34: 344-353. 10.1097/01.CCM.0000194725.48928.3ACrossRefPubMed Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D: Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34: 344-353. 10.1097/01.CCM.0000194725.48928.3ACrossRefPubMed
2.
go back to reference Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y: Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006, 50: 43-48. 10.1128/AAC.50.1.43-48.2006PubMedCentralCrossRefPubMed Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y: Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006, 50: 43-48. 10.1128/AAC.50.1.43-48.2006PubMedCentralCrossRefPubMed
3.
go back to reference Berthelot P, Grattard F, Mallaval FO, Ros A, Lucht F, Pozzetto B: Epidemiology of nosocomial infections due to Pseudomonas aeruginosa , Burkholderia cepacia and Stenotrophomonas maltophilia . Pathol Biol 2005, 53: 341-348. 10.1016/j.patbio.2004.09.006CrossRefPubMed Berthelot P, Grattard F, Mallaval FO, Ros A, Lucht F, Pozzetto B: Epidemiology of nosocomial infections due to Pseudomonas aeruginosa , Burkholderia cepacia and Stenotrophomonas maltophilia . Pathol Biol 2005, 53: 341-348. 10.1016/j.patbio.2004.09.006CrossRefPubMed
4.
go back to reference Nseir S, Ader F, Marquette CH, Durocher A: Impact of fluoroquinolone use on multidrug-resistant bacteria emergence. Pathol Biol 2005, 53: 470-475. 10.1016/j.patbio.2005.07.008CrossRefPubMed Nseir S, Ader F, Marquette CH, Durocher A: Impact of fluoroquinolone use on multidrug-resistant bacteria emergence. Pathol Biol 2005, 53: 470-475. 10.1016/j.patbio.2005.07.008CrossRefPubMed
5.
go back to reference Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH: Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005, 49: 1306-1311. 10.1128/AAC.49.4.1306-1311.2005PubMedCentralCrossRefPubMed Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH: Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005, 49: 1306-1311. 10.1128/AAC.49.4.1306-1311.2005PubMedCentralCrossRefPubMed
6.
go back to reference Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW: Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005, 49: 760-766. 10.1128/AAC.49.2.760-766.2005PubMedCentralCrossRefPubMed Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW: Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005, 49: 760-766. 10.1128/AAC.49.2.760-766.2005PubMedCentralCrossRefPubMed
7.
go back to reference Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J: Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis 2001,32(Suppl 2):S104-S113. 10.1086/320183CrossRefPubMed Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J: Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis 2001,32(Suppl 2):S104-S113. 10.1086/320183CrossRefPubMed
8.
go back to reference Senol E: Stenotrophomonas maltophilia : the significance and role as a nosocomial pathogen. J Hosp Infect 2004, 57: 1-7. 10.1016/j.jhin.2004.01.033CrossRefPubMed Senol E: Stenotrophomonas maltophilia : the significance and role as a nosocomial pathogen. J Hosp Infect 2004, 57: 1-7. 10.1016/j.jhin.2004.01.033CrossRefPubMed
9.
go back to reference Ferrara AM: Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia. Int J Antimicrob Agents 2006, 27: 183-195. 10.1016/j.ijantimicag.2005.11.005CrossRefPubMed Ferrara AM: Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia. Int J Antimicrob Agents 2006, 27: 183-195. 10.1016/j.ijantimicag.2005.11.005CrossRefPubMed
10.
go back to reference Looney WJ: Role of Stenotrophomonas maltophilia in hospital-acquired infection. Br J Biomed Sci 2005, 62: 145-154.PubMed Looney WJ: Role of Stenotrophomonas maltophilia in hospital-acquired infection. Br J Biomed Sci 2005, 62: 145-154.PubMed
11.
go back to reference Pathmanathan A, Waterer GW: Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection. Eur Respir J 2005, 25: 911-914. 10.1183/09031936.05.00096704CrossRefPubMed Pathmanathan A, Waterer GW: Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection. Eur Respir J 2005, 25: 911-914. 10.1183/09031936.05.00096704CrossRefPubMed
12.
go back to reference Tsai WP, Chen CL, Ko WC, Pan SC: Stenotrophomonas maltophilia bacteremia in burn patients. Burns 2006, 32: 155-158. 10.1016/j.burns.2005.08.016CrossRefPubMed Tsai WP, Chen CL, Ko WC, Pan SC: Stenotrophomonas maltophilia bacteremia in burn patients. Burns 2006, 32: 155-158. 10.1016/j.burns.2005.08.016CrossRefPubMed
13.
go back to reference Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW: Bacteraemia due to Stenotrophomonas maltophilia : an analysis of 45 episodes. J Infect 2002, 45: 47-53. 10.1053/jinf.2002.0978CrossRefPubMed Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW: Bacteraemia due to Stenotrophomonas maltophilia : an analysis of 45 episodes. J Infect 2002, 45: 47-53. 10.1053/jinf.2002.0978CrossRefPubMed
14.
go back to reference Lai CH, Chi CY, Chen HP, Chen TL, Lai CJ, Fung CP, Yu KW, Wong WW, Liu CY: Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 2004, 37: 350-358.PubMed Lai CH, Chi CY, Chen HP, Chen TL, Lai CJ, Fung CP, Yu KW, Wong WW, Liu CY: Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 2004, 37: 350-358.PubMed
15.
go back to reference Wang WS, Liu CP, Lee CM, Huang FY: Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J Microbiol Immunol Infect 2004, 37: 359-365.PubMed Wang WS, Liu CP, Lee CM, Huang FY: Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J Microbiol Immunol Infect 2004, 37: 359-365.PubMed
16.
go back to reference Hanes SD, Demirkan K, Tolley E, Boucher BA, Croce MA, Wood GC, Fabian TC: Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002, 35: 228-235. 10.1086/341022CrossRefPubMed Hanes SD, Demirkan K, Tolley E, Boucher BA, Croce MA, Wood GC, Fabian TC: Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002, 35: 228-235. 10.1086/341022CrossRefPubMed
17.
go back to reference Nseir S, Di Pompeo C, Soubrier S, Lenci H, Delour P, Onimus T, Saulnier F, Mathieu D, Durocher A: Effect of ventilator-associated tracheobronchitis on outcome in patients without chronic respiratory failure: a case-control study. Crit Care 2005, 9: R238-R245. 10.1186/cc3508PubMedCentralCrossRefPubMed Nseir S, Di Pompeo C, Soubrier S, Lenci H, Delour P, Onimus T, Saulnier F, Mathieu D, Durocher A: Effect of ventilator-associated tracheobronchitis on outcome in patients without chronic respiratory failure: a case-control study. Crit Care 2005, 9: R238-R245. 10.1186/cc3508PubMedCentralCrossRefPubMed
18.
go back to reference Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988, 16: 128-140. 10.1016/0196-6553(88)90053-3CrossRefPubMed Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988, 16: 128-140. 10.1016/0196-6553(88)90053-3CrossRefPubMed
19.
go back to reference Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society Am J Respir Crit Care Med 1995, 152: S77-121. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society Am J Respir Crit Care Med 1995, 152: S77-121.
20.
go back to reference Torres A, Aznar R, Gatell JM, Jimenez P, Gonzalez J, Ferrer A, Celis R, Rodriguez-Roisin R: Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990, 142: 523-528.CrossRefPubMed Torres A, Aznar R, Gatell JM, Jimenez P, Gonzalez J, Ferrer A, Celis R, Rodriguez-Roisin R: Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990, 142: 523-528.CrossRefPubMed
21.
go back to reference Nseir S, Di Pompeo C, Soubrier S, Cavestri B, Jozefowicz E, Saulnier F, Durocher A: Impact of ventilator-associated pneumonia on outcome in patients with COPD. Chest 2005, 128: 1650-1656. 10.1378/chest.128.3.1650CrossRefPubMed Nseir S, Di Pompeo C, Soubrier S, Cavestri B, Jozefowicz E, Saulnier F, Durocher A: Impact of ventilator-associated pneumonia on outcome in patients with COPD. Chest 2005, 128: 1650-1656. 10.1378/chest.128.3.1650CrossRefPubMed
22.
go back to reference Reynolds HY: Bacterial adherence to respiratory tract mucosa – a dynamic interaction leading to colonization. Semin Respir Infect 1987, 2: 8-19.PubMed Reynolds HY: Bacterial adherence to respiratory tract mucosa – a dynamic interaction leading to colonization. Semin Respir Infect 1987, 2: 8-19.PubMed
23.
go back to reference Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M: Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999, 116: 40-46. 10.1378/chest.116.1.40CrossRefPubMed Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M: Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999, 116: 40-46. 10.1378/chest.116.1.40CrossRefPubMed
24.
go back to reference Wilson R: Treatment of COPD exacerbations: antibiotics. Eur Respir Rev 2005, 14: 32-38.CrossRef Wilson R: Treatment of COPD exacerbations: antibiotics. Eur Respir Rev 2005, 14: 32-38.CrossRef
25.
go back to reference Nseir S, Di Pompeo C, Soubrier S, Delour P, Lenci H, Roussel-Delvallez M, Onimus T, Saulnier F, Mathieu D, Durocher A: First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med 2005, 33: 283-289. 10.1097/01.CCM.0000152230.53473.A1CrossRefPubMed Nseir S, Di Pompeo C, Soubrier S, Delour P, Lenci H, Roussel-Delvallez M, Onimus T, Saulnier F, Mathieu D, Durocher A: First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med 2005, 33: 283-289. 10.1097/01.CCM.0000152230.53473.A1CrossRefPubMed
26.
go back to reference Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290: 2588-2598. 10.1001/jama.290.19.2588CrossRefPubMed Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290: 2588-2598. 10.1001/jama.290.19.2588CrossRefPubMed
27.
go back to reference Micek ST, Ward S, Fraser VJ, Kollef MH: A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004, 125: 1791-1799. 10.1378/chest.125.5.1791CrossRefPubMed Micek ST, Ward S, Fraser VJ, Kollef MH: A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004, 125: 1791-1799. 10.1378/chest.125.5.1791CrossRefPubMed
28.
go back to reference Luna CM, Blanzaco D, Niederman MS, Matarucco W, Baredes NC, Desmery P, Palizas F, Menga G, Rios F, Apezteguia C: Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003, 31: 676-682. 10.1097/01.CCM.0000055380.86458.1ECrossRefPubMed Luna CM, Blanzaco D, Niederman MS, Matarucco W, Baredes NC, Desmery P, Palizas F, Menga G, Rios F, Apezteguia C: Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003, 31: 676-682. 10.1097/01.CCM.0000055380.86458.1ECrossRefPubMed
29.
go back to reference Lambiase A, Raia V, Del Pezzo M, Sepe A, Carnovale V, Rossano F: Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect Dis 2006, 6: 4. 10.1186/1471-2334-6-4PubMedCentralCrossRefPubMed Lambiase A, Raia V, Del Pezzo M, Sepe A, Carnovale V, Rossano F: Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect Dis 2006, 6: 4. 10.1186/1471-2334-6-4PubMedCentralCrossRefPubMed
30.
go back to reference Steinkamp G, Wiedemann B, Rietschel E, Krahl A, Gielen J, Barmeier H, Ratjen F: Prospective evaluation of emerging bacteria in cystic fibrosis. J Cyst Fibros 2005, 4: 41-48. 10.1016/j.jcf.2004.10.002CrossRefPubMed Steinkamp G, Wiedemann B, Rietschel E, Krahl A, Gielen J, Barmeier H, Ratjen F: Prospective evaluation of emerging bacteria in cystic fibrosis. J Cyst Fibros 2005, 4: 41-48. 10.1016/j.jcf.2004.10.002CrossRefPubMed
31.
go back to reference Marchac V, Equi A, Bihan-Benjamin C, Hodson M, Bush A: Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur Respir J 2004, 23: 98-102. 10.1183/09031936.03.00007203CrossRefPubMed Marchac V, Equi A, Bihan-Benjamin C, Hodson M, Bush A: Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur Respir J 2004, 23: 98-102. 10.1183/09031936.03.00007203CrossRefPubMed
32.
go back to reference Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW: Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004, 59: 955-959. 10.1136/thx.2003.017707PubMedCentralCrossRefPubMed Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW: Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004, 59: 955-959. 10.1136/thx.2003.017707PubMedCentralCrossRefPubMed
33.
go back to reference Villarino ME, Stevens LE, Schable B, Mayers G, Miller JM, Burke JP, Jarvis WR: Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol 1992, 13: 201-206.CrossRefPubMed Villarino ME, Stevens LE, Schable B, Mayers G, Miller JM, Burke JP, Jarvis WR: Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol 1992, 13: 201-206.CrossRefPubMed
34.
go back to reference Sanyal SC, Mokaddas EM: The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother 1999, 11: 28-33.CrossRefPubMed Sanyal SC, Mokaddas EM: The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother 1999, 11: 28-33.CrossRefPubMed
35.
go back to reference Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR: Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 2002, 34: 1653-1656. 10.1086/340707CrossRefPubMed Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR: Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 2002, 34: 1653-1656. 10.1086/340707CrossRefPubMed
36.
go back to reference VanCouwenberghe CJ, Farver TB, Cohen SH: Risk factorsassociated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. Infect Control Hosp Epidemiol 1997, 18: 316-321.CrossRefPubMed VanCouwenberghe CJ, Farver TB, Cohen SH: Risk factorsassociated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. Infect Control Hosp Epidemiol 1997, 18: 316-321.CrossRefPubMed
37.
go back to reference Rolston KV, Kontoyiannis DP, Yadegarynia D, Raad II: Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. Diagn Microbiol Infect Dis 2005, 51: 215-218. 10.1016/j.diagmicrobio.2004.11.002CrossRefPubMed Rolston KV, Kontoyiannis DP, Yadegarynia D, Raad II: Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. Diagn Microbiol Infect Dis 2005, 51: 215-218. 10.1016/j.diagmicrobio.2004.11.002CrossRefPubMed
38.
go back to reference Wunderink RG: Nosocomial pneumonia, including ventilator-associated pneumonia. Proc Am Thorac Soc 2005, 2: 440-444. 10.1513/pats.2005080-83JSCrossRefPubMed Wunderink RG: Nosocomial pneumonia, including ventilator-associated pneumonia. Proc Am Thorac Soc 2005, 2: 440-444. 10.1513/pats.2005080-83JSCrossRefPubMed
39.
go back to reference Safdar N, Maki DG: The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus , enterococcus, gram-negative bacilli, Clostridium difficile , and Candida. Ann Intern Med 2002, 136: 834-844.CrossRefPubMed Safdar N, Maki DG: The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus , enterococcus, gram-negative bacilli, Clostridium difficile , and Candida. Ann Intern Med 2002, 136: 834-844.CrossRefPubMed
40.
go back to reference Tsiodras S, Pittet D, Carmeli Y, Eliopoulos G, Boucher H, Harbarth S: Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 2000, 32: 651-656. 10.1080/003655400459577CrossRefPubMed Tsiodras S, Pittet D, Carmeli Y, Eliopoulos G, Boucher H, Harbarth S: Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 2000, 32: 651-656. 10.1080/003655400459577CrossRefPubMed
41.
go back to reference Gulcan H, Kuzucu C, Durmaz R: Nosocomial Stenotrophomonas maltophilia cross-infection: three cases in newborns. Am J Infect Control 2004, 32: 365-368. 10.1016/j.ajic.2004.07.003CrossRefPubMed Gulcan H, Kuzucu C, Durmaz R: Nosocomial Stenotrophomonas maltophilia cross-infection: three cases in newborns. Am J Infect Control 2004, 32: 365-368. 10.1016/j.ajic.2004.07.003CrossRefPubMed
42.
go back to reference Lanotte P, Cantagrel S, Mereghetti L, Marchand S, Van der MN, Besnier JM, Laugier J, Quentin R: Spread of Stenotrophomonas maltophilia colonization in a pediatric intensive care unit detected by monitoring tracheal bacterial carriage and molecular typing. Clin Microbiol Infect 2003, 9: 1142-1147. 10.1046/j.1469-0691.2003.00785.xCrossRefPubMed Lanotte P, Cantagrel S, Mereghetti L, Marchand S, Van der MN, Besnier JM, Laugier J, Quentin R: Spread of Stenotrophomonas maltophilia colonization in a pediatric intensive care unit detected by monitoring tracheal bacterial carriage and molecular typing. Clin Microbiol Infect 2003, 9: 1142-1147. 10.1046/j.1469-0691.2003.00785.xCrossRefPubMed
Metadata
Title
Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome
Authors
Saad Nseir
Christophe Di Pompeo
Hélène Brisson
Florent Dewavrin
Stéphanie Tissier
Maimouna Diarra
Marie Boulo
Alain Durocher
Publication date
01-10-2006
Publisher
BioMed Central
Published in
Critical Care / Issue 5/2006
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc5063

Other articles of this Issue 5/2006

Critical Care 5/2006 Go to the issue